Literature DB >> 7480547

The stimulation of cholecystokinin receptors in the rostral nucleus accumbens significantly antagonizes the EEG and behavioural effects induced by phencyclidine in rats.

P Popoli1, R Reggio, A Pèzzola, A Scotti de Carolis.   

Abstract

The influence of cholecystokinin (CCK), bilaterally injected into the rostral nucleus accumbens, on the EEG and behavioural effects induced by phencyclidine (PCP) has been studied in rats. CCK (10 ng) significantly inhibited PCP-induced EEG effects (increase of spectral power with respect to pre-drug tracing; increase of relative power distribution in the slowest frequency bands), and behavioural effects (circling and ataxia). The inhibitory effects of CCK were completely antagonized by 1 ng PD 135-158, a selective CCKB receptor antagonist, but not by lorglumide (1 microgram), a selective CCKA receptor antagonist. Since the effects induced by PCP in rodents have been proposed to be an experimental correlate of the psychotic symptoms it induces in humans, these results indicate that CCK may act as a neuroleptic. They also suggest that CCKB receptors located in the rostral nucleus accumbens may be involved in the neuroleptic-like activity of CCK.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7480547     DOI: 10.1007/bf02246188

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  39 in total

1.  Opposite effects of cholecystokinin octapeptide (CCK-8) and tetrapeptide (CCK-4) after injection into the caudal part of the nucleus accumbens or into its rostral part and the cerebral ventricles.

Authors:  P De Witte; C Heidbreder; B Roques; J J Vanderhaeghen
Journal:  Neurochem Int       Date:  1987       Impact factor: 3.921

2.  The effects of phencyclidine on the uptake of 3H-catecholamines by rat striatal and hypothalamic synaptosomes.

Authors:  R E Garey; R G Heath
Journal:  Life Sci       Date:  1976-05-15       Impact factor: 5.037

Review 3.  Cholecystokinin and schizophrenia.

Authors:  N P Nair; S Lal; D M Bloom
Journal:  Prog Brain Res       Date:  1986       Impact factor: 2.453

4.  Evidence that type A CCK receptors facilitate dopamine efflux in rat brain.

Authors:  T W Vickroy; B R Bianchi; J F Kerwin; H Kopecka; A M Nadzan
Journal:  Eur J Pharmacol       Date:  1988-08-02       Impact factor: 4.432

5.  Behavioural and electoencephalographic interactions between haloperidol and PCP/sigma ligands in the rat.

Authors:  S Sagratella; A Scotti de Carolis; A Pèzzola; P Popoli
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 6.  The use of cholecystokinin in schizophrenia: a review.

Authors:  S A Montgomery; M C Green
Journal:  Psychol Med       Date:  1988-08       Impact factor: 7.723

7.  Antagonism of N-methyl-D-aspartate-induced transmitter release in the rat striatum by phencyclidine-like drugs and its relationship to turning behavior.

Authors:  L D Snell; K M Johnson
Journal:  J Pharmacol Exp Ther       Date:  1985-10       Impact factor: 4.030

8.  Differential interaction of cholecystokinin with morphine and phencyclidine: effects on operant behavior in pigeons.

Authors:  P J Winsauer; D M Thompson
Journal:  Pharmacol Biochem Behav       Date:  1992-01       Impact factor: 3.533

9.  Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity: evidence for rostral-caudal differences in accumbens CCK function.

Authors:  F J Vaccarino; J Rankin
Journal:  Behav Neurosci       Date:  1989-08       Impact factor: 1.912

10.  Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms.

Authors:  F H Marshall; S Barnes; J Hughes; G N Woodruff; J C Hunter
Journal:  J Neurochem       Date:  1991-03       Impact factor: 5.372

View more
  1 in total

1.  A cholecystokinin-mediated pathway to the paraventricular thalamus is recruited in chronically stressed rats and regulates hypothalamic-pituitary-adrenal function.

Authors:  S Bhatnagar; V Viau; A Chu; L Soriano; O C Meijer; M F Dallman
Journal:  J Neurosci       Date:  2000-07-15       Impact factor: 6.167

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.